结外鼻型NK/T细胞淋巴瘤的内科治疗进展

doi:10.3760/cma.j.issn.1673-422X.2015.01.019

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (1): 71-73.doi: 10.3760/cma.j.issn.1673-422X.2015.01.019

结外鼻型NK/T细胞淋巴瘤的内科治疗进展

王静静, 董梅

100021北京协和医学院中国医学科学院肿瘤医院肿瘤医院肿瘤内科

收稿日期:2014-06-10 修回日期:2014-08-19 出版日期:2015-01-08 发布日期:2015-01-07
通讯作者: 董梅 E-mail:dongmei030224@163.com
基金资助:
中国医学科学院肿瘤医院重点科研课题（LC2010A05）

Recent advances in the internal medical management of extranodal nasal type NK/T cell lymphoma

Wang Jingjing, Dong Mei

Department of Medical Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Received:2014-06-10 Revised:2014-08-19 Online:2015-01-08 Published:2015-01-07
Contact: Dong Mei E-mail:dongmei030224@163.com

摘要/Abstract

摘要： 结外鼻型自然杀伤（NK）/T细胞淋巴瘤是一种高度侵袭性非霍奇金淋巴瘤，因发病率低，缺乏大样本前瞻性随机对照研究，仍未确定标准一线化疗方案。因多药耐药基因1高表达，对蒽环类药物为主的常规化疗抗拒。近年来出现一些有效率较高的方案，含左旋门冬酰胺酶或吉西他滨的方案近期有效率高，可作为首选方案，而靶向治疗、免疫调节治疗和造血干细胞移植仍在探索之中。

关键词: 淋巴瘤, 结外NK/T细胞, 药物疗法, 造血干细胞移植

Abstract: Extranodal nasal type NK/T cell lymphoma (ENKTL) is a highly aggressive nonHodgkin lymphoma. Due to its low occurrence even in prevalent areas, there has been no large sample randomized controlled clinical trials. Therefore, no standard therapeutic strategy is currently identified in this disease. Tumor cells are insensitive to conventional anthracyclinescontaining chemotherapy because of high expression of multidrug resistant gene 1. Regimens that incorporate the use of Lasparaginase or gemcitabine result in substantial improvements in overall response rate and are promising treatment for ENKTL. Targeted therapy, immunomodulatory therapy and hematopoietic stem cell transplantation are still under research.

Key words: Lymphoma, extranodal NK T cell, Drug therapy, Hematopoietic stem cell transplantation

王静静, 董梅. 结外鼻型NK/T细胞淋巴瘤的内科治疗进展[J]. 国际肿瘤学杂志, 2015, 42(1): 71-73.

Wang Jingjing, Dong Mei. Recent advances in the internal medical management of extranodal nasal type NK/T cell lymphoma[J]. Journal of International Oncology, 2015, 42(1): 71-73.

参考文献

［1］ Vose J, Armitage J, Weisenburger D, et al. International peripheral Tcell and natural killer/Tcell lymphoma study: pathology findings and clinical outcomes［J］. J Clin Oncol, 2008, 26(25): 4124-4130. ［2］ Li YX, Liu QF, Wang WH, et al. Failure patterns and clinical implications in early stage nasal natural killer/Tcell lymphoma treated with primary radiotherapy［J］. Cancer, 2011, 117(22): 5203-5211. ［3］ Wang B, Li XQ, Ma X, et al. Immunohistochemical expression and clinical significance of Pglycoprotein in previously untreated extranodal NK/Tcell lymphoma, nasal type［J］. Am J Hematol, 2008, 83(10): 795-799. ［4］ Yamaguchi M, Suzuki R, Kwong YL, et al. Phase Ⅰ study of dexamethasone, methotrexate, ifosfamide, Lasparaginase, and etoposide (SMLILE) chemotherapy for advancedstage, relapsed or refractory extranodal natural killer (NK)/Tcell lymphoma and leukemia［J］. Cancer Sci, 2008, 99(5): 1016-1020. ［5］ Yamaguchi M, Kwong YL, Kim WS, et al. Phase Ⅱ study of SMILE chemotherapy for newly diagnosed stage Ⅳ, relapsed, or refractory extranodal natural killer (NK)/Tcell lymphoma, nasal type: the NKcell tumor study group study［J］. J Clin Oncol, 2011, 29(33): 44104416. ［6］ Jaccard A, Gachard N, Marin B, et al. Efficacy of Lasparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/Tcell lymphoma, a phase 2 study［J］. Blood, 2011, 117(6): 1834-1839. ［7］ Dong M, He XH, Liu P, et al. Gemcitabinebased combination regimen in patients with peripheral Tcell lymphoma［J］. Med Oncol, 2013, 30(1): 351. ［8］ Ahn HK, Kim SJ, Hwang DW, et al. Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/Tcell lymphoma［J］. Invest New Drugs, 2013, 31(2): 469-472. ［9］ Lee J, Suh C, Kang HJ, et al. Phase Ⅰ study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive Tcell or NK/Tcell lymphoma［J］. Ann Oncol, 2008, 19(12): 2079-2083. ［10］ Kim SJ, Yoon DH, Kang HJ, et al. Bortezomib in combination with CHOP as firstline treatment for patients with stage Ⅲ/Ⅳ peripheral Tcell lymphomas: a multicentre, singlearm, phase 2 trial［J］. Eur J Cancer, 2012, 48(17): 3223-3231. ［11］ Kim SJ, Kim K, Park Y, et al. Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral Tcell lymphoma: analysis of efficacy and toxicity［J］. Invest New Drugs, 2012, 30(1): 368375. ［12］ Piccaluga PP, Agostinelli C, Righi S, et al. Expression of CD52 in peripheral Tcell lymphoma［J］. Haematologica, 2007, 92(4): 566-567. ［13］ Huang H, Lin Z, Lin X, et al. Longterm outcomes of patients with newly diagnosed extranodal natural killer/Tcell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a singleinstitution experience［J］. Leuk Lymphoma, 2011, 52(6): 1041-1048. ［14］ Kim BS, Kim DW, Im SA, et al. Effective secondline chemotherapy for extranodal NK/Tcell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone［J］. Ann Oncol, 2009, 20(1): 121-128. ［15］ Lee J, Au WY, Park MJ, et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/Tcell lymphoma: a multinational, matched controlled study［J］. Biol Blood Marrow Transplant, 2008, 14(12): 1356-1364. ［16］ Murashige N, Kami M, Kishi Y, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killercell neoplasms［J］. Br J Haematol, 2005, 130(4): 561-567.

[1]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[2]	张洁, 范玲, 李杰, 温华, 苏媛媛, 路宁, 张明鑫. 原发性胰腺淋巴瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 316-320.
[3]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[4]	李晨曦, 赵宏伟. 二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[5]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[6]	耿睿, 马俊强, 郭强, 牛钊峰. 老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.
[7]	陈怡, 韩靓, 蔡雳. 头颈部肿瘤患者化疗性口腔黏膜炎发生的多因素分析[J]. 国际肿瘤学杂志, 2022, 49(9): 521-525.
[8]	殷运燕, 李慧, 李雨晨, 惠慧, 许景艳. 组蛋白去乙酰化酶抑制剂在非霍奇金淋巴瘤中的临床应用[J]. 国际肿瘤学杂志, 2022, 49(8): 499-504.
[9]	褚雪镭, 毛昀, 薛鹏, 李林潞, 陈美池, 袁淳晟, 秦晓艳, 朱世杰. 化疗剂量强度对晚期结肠癌患者近期疗效的影响：基于真实世界数据研究[J]. 国际肿瘤学杂志, 2022, 49(7): 408-415.
[10]	王柳雪, 席晓平, 刘静静, 沈国民, 杨海平. 二甲双胍在非霍奇金淋巴瘤中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(7): 436-440.
[11]	韩丛丛, 付帅, 谢超, 张建军, 张秋景, 祝情情, 刘杰. 吉非替尼、培美曲塞和贝伐珠单抗一线治疗EGFR突变晚期肺腺癌的有效性和安全性[J]. 国际肿瘤学杂志, 2022, 49(6): 376-379.
[12]	唐琳, 相明月, 张建波, 王丽丽, 巩合义, 韩大力. 卡瑞利珠单抗联合阿帕替尼及化疗二线或以上治疗HER-2阴性晚期胃癌的临床疗效及安全性[J]. 国际肿瘤学杂志, 2022, 49(5): 276-281.
[13]	张绍鹏, 孔远, 潘国强, 朱丽, 王大广. 全身化疗联合腹腔热灌注治疗胃癌1例[J]. 国际肿瘤学杂志, 2022, 49(5): 316-318.
[14]	孙淑琴, 钱秋红, 张友忠. 盆腔原发弥漫性大B细胞淋巴瘤1例[J]. 国际肿瘤学杂志, 2022, 49(5): 319-320.
[15]	高世乐, 芦东徽, 刘美琴, 徐兴军, 马欢, 张羽. 阿帕替尼联合化疗在晚期非小细胞肺癌患者中的临床疗效和最佳剂量探讨[J]. 国际肿瘤学杂志, 2022, 49(3): 140-145.

结外鼻型NK/T细胞淋巴瘤的内科治疗进展

Recent advances in the internal medical management of extranodal nasal type NK/T cell lymphoma

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价